Abigail Brooks, MA

Kim explains how poor sleep is linked to negative impacts on mental health, physical health, and frailty after liver transplantation.

Treatment with elafibranor (Iqirvo) improved prognostic GLOBE and UK-PBC scores as early as week 4 in the phase 3 ELATIVE trial.

Cohen explains patient perspectives about how healthcare providers can help address the lack of diversity in chronic HBV clinical trials.

Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.

Stine reviews findings from a posthoc analysis of the NASHFit trial suggesting the impact of exercise on MASH resolution, even without weight loss.

Zoi Papalamprakopoulou, MD, explains telehealth’s potential to aid HCV treatment in high-risk populations and how patients perceive this care modality.

Zhang describes how a novel multidisciplinary care clinic has helped reduce relapse after transplant in patients with alcohol-associated liver disease.

New phase 2b data suggest a combination of VTP-300 and low-dose nivolumab can stimulate immune response and induce HBV functional cure.

Findings from a 2.5-year interim analysis from the ongoing phase 3 ASSURE study highlight seladelpar’s sustained efficacy and long-term safety for PBC.

In areas where HBV immune globulin is not available, maternal TDF therapy at week 16 and infant HBV vaccination can prevent mother-to-child transmission.

Initiation of population-wide CKD screening followed by conventional CKD treatment plus SGLT2 inhibitors at 55 years of age was cost-effective.

The risk score uses routine clinical data to assess hepatocellular carcinoma risk in patients without viral hepatitis or hepatic decompensation.

The CRL is consistent with the outcome of a September Gastrointestinal Drugs Advisory Committee meeting.

Alkhouri explains the first real-world data on the use of resmetirom (Rezdiffra) in patients with MASH and how they compare to clinical trial findings.

Treatment with the novel selective endothelin receptor type A antagonist alongside standard care reduced UPCR in patients with IgAN in a phase 2 trial.

Phase 1b data support proof-of-principle for EBX-102 across microbiome and clinical assessments as well as inflammatory biomarkers for cirrhosis.

Braden Kuo, MD, explains how the gas-sensing capsule compares to the FDA-cleared, but now discontinued, SmartPill wireless motility capsule.

The study is one of the first to report United States IgAN incidence based on a large racially and ethnically diverse cohort.

Satish Rao, MD, PhD, explains how a stool diary app may provide incremental benefit and facilitate treatment monitoring with the vibrating capsule.

This nephrology month in review spotlights HCPLive’s coverage of ASN Kidney Week, the debut of a new podcast, and new research on IgA nephropathy.

Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.

Phase 3, 3b, and 4 clinical trials will provide long-term insight into the use of elafibranor in different PBC patient populations and real-world settings.

This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.

Findings suggest HS is associated with pregnancy complications and adverse outcomes for both mothers and offspring.

This month in review spotlights HCPLive’s coverage of the ACG 2024 meeting, GI pipeline updates, and other news and research from October.

Headline results from part 1 of the phase 3 ESSENCE trial highlight semaglutide 2.4 mg’s benefits for fibrosis and steatohepatitis in patients with MASH.

Anthony Kerbage, MD, describes disparities in 21 IBS clinical trials whose data was used to support the FDA approvals of 7 IBS-C and IBS-D drugs.

Mohammad Abuassi, MD, explains how classifying IBS based on triggers can aid the development of effective, personalized approaches to management.

Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.

Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.